Drug resistance in HIV patients starting first-line treatment in Germany

14% of untreated HIV-infected individuals in Germany exhibit resistance-associated mutations before starting first-line antiretroviral therapy.

• Resistance-associated mutations were detected in 20 out of 143 patients, indicating a prevalence of 14%.
• Mutations associated with nucleoside reverse transcriptase inhibitor (NRTI) resistance were found in 10.5% of cases.
• Non-nucleoside reverse transcriptase inhibitor (NNRTI) resistance mutations appeared in 2.8% of the patients.
• Protease inhibitor (PI) resistance was identified in 2.1% of individuals.
• Multi-class resistance and revertant variants of resistant strains were found in low percentages, at 2.1% and 4.2%, respectively.
• No significant differences were observed in demographic or clinical parameters between patients with and without resistance mutations.

Simplified